• Mashup Score: 7
    Anti-TIGIT therapies for solid tumors: a systematic review - 1 year(s) ago

    Programmed death-ligand 1[PD-(L)1], cytotoxic T-lymphocyte associated protein 4 (CTLA-4), and lymphocyte-activation gene 3 (LAG-3) inhibitors are recent breakthroughs in cancer treatment, however not all patients benefit from it. Thus new therapies are under investigation, such as anti-TIGIT [anti-T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif…

    Source: Esmo Open
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of OncoAlert
      OncoAlert

      RT @lindamahj: TIGIT review 🙌 https://t.co/wfK6BPO90g

  • Mashup Score: 8
    Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy - 1 year(s) ago

    BRAF activation occurs as part of the mitogen-activated protein kinase (MAPK) cellular signaling pathway which leads to increased cellular proliferation and survival. Mutations in BRAF can result in unbridled activation of downstream kinases with subsequent uncontrolled cellular growth that formulate the basis for oncogenesis in multiple tumor types. Targeting BRAF by selective inhibitors has…

    Source: Esmo Open
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VivekSubbiah
      VivekSubbiah

      Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy @ESMO_Open @myESMO #BRAF #PrecisionMedicine https://t.co/AGFS54BvDS

  • Mashup Score: 0
    Anti-TIGIT therapies for solid tumors: a systematic review - 1 year(s) ago

    Programmed death-ligand 1[PD-(L)1], cytotoxic T-lymphocyte associated protein 4 (CTLA-4), and lymphocyte-activation gene 3 (LAG-3) inhibitors are recent breakthroughs in cancer treatment, however not all patients benefit from it. Thus new therapies are under investigation, such as anti-TIGIT [anti-T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif…

    Source: Esmo Open
    Categories: Latest Headlines, Oncologists2
    Tweet Tweets with this article
    • Profile photo of VriesElisabeth
      VriesElisabeth

      Anti-TIGIT therapies for solid tumors: a systematic review https://t.co/hdoAtfArfR

  • Mashup Score: 2
    Anti-TIGIT therapies for solid tumors: a systematic review - 1 year(s) ago

    Programmed death-ligand 1[PD-(L)1], cytotoxic T-lymphocyte associated protein 4 (CTLA-4), and lymphocyte-activation gene 3 (LAG-3) inhibitors are recent breakthroughs in cancer treatment, however not all patients benefit from it. Thus new therapies are under investigation, such as anti-TIGIT [anti-T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif…

    Source: Esmo Open
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of StephenVLiu
      StephenVLiu

      Review of #TIGIT online @ESMO_Open from Dr. @barlesi and team. Helpful overview of mechanism and anti-TIGIT molecules in development including tiragolumab, domvanalimab, vibostolimab, ociperlimab, EOS884448 and others. https://t.co/V6ZfkmwA8N

  • Mashup Score: 11
    How I treat diffuse large B-cell lymphoma - 1 year(s) ago

    Diffuse large B-cell lymphoma (DLBCL) is usually treated with chemoimmunotherapy in curative intention at initial diagnosis. Novel agents have improved the prognosis of high-risk patients in the front-line and relapsed setting and more accurate prognostic tools enable less intensive treatment for low-risk patients, while maintaining their good prognosis. Here, we summarize our approach to DLBCL…

    Source: Esmo Open
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of CARTTherapy
      CARTTherapy

      RT @smbenlazar: How I treat diffuse large B-cell lymphoma https://t.co/KnB3vk08Ek #lymsm https://t.co/0IiU866WSV

  • Mashup Score: 0
    Cancer burden in adolescents and young adults in Europe - 1 year(s) ago

    Cancer epidemiology is unique in adolescents and young adults (AYAs; aged 15-39 years). The European Society for Medical Oncology/European Society for Paediatric Oncology (ESMO/SIOPE) AYA Working Group aims to describe the burden of cancers in AYAs in Europe and across European Union (EU) countries.

    Source: Esmo Open
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of myESMO
      myESMO

      1/2 A recent ESMO-@SIOPEurope paper highlighted the cancer burden of AYA cancers. Cancer in this population is rare, albeit increasing in the current era. Actions, requirements & initiatives are needed to reduce this burden. https://t.co/VZsJnLQsLO #AYACSM #AYACancer https://t.co/B3IU5YcfEm

  • Mashup Score: 0
    FOLFOXIRI plus bevacizumab as standard of care for first-line treatment in patients with advanced colon cancer - 1 year(s) ago

    The first therapeutic decision is of paramount importance in any patient with an advanced solid tumor and should be made after considering many clinical features related to the patient condition and to the extension and biology of the tumor, as well as the tolerance profile of the drug or combinations of drugs to be used. This principle is of particular importance when considering the first…

    Source: Esmo Open
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ESMO_Open
      ESMO_Open

      Would you vote differently after reading the current discussion: FOLFOXIRI plus bevacizumab as standard of care for first-line treatment in patients with advanced #coloncancer @OncoAlert @myESMO @cczielinski @PaoloBossi6 https://t.co/4lyTZAoWxR https://t.co/3mp9wcanjK

  • Mashup Score: 0
    Controversies in NSCLC: which second-line strategy after chemo-immunotherapy? - 1 year(s) ago

    Over the last 5 years we have witnessed revolutionary improvements in the first-line setting for advanced non-small-cell lung cancer (NSCLC): the introduction of combinations with platinum-doublets and immunotherapy as standard treatment of treatment-naive NSCLC has led to better response rates and overall survival (OS).1-5

    Source: Esmo Open
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ESMO_Open
      ESMO_Open

      Would you vote differently after reading the current discussion: Controversies in NSCLC: which second-line strategy after chemo-immunotherapy? @OncoAlert @myESMO @cczielinski @PaoloBossi6 https://t.co/rf3HrUfdPT https://t.co/6LzFPnUdUB

  • Mashup Score: 0
    Controversies in NSCLC: which second-line strategy after chemo-immunotherapy? - 1 year(s) ago

    Over the last 5 years we have witnessed revolutionary improvements in the first-line setting for advanced non-small-cell lung cancer (NSCLC): the introduction of combinations with platinum-doublets and immunotherapy as standard treatment of treatment-naive NSCLC has led to better response rates and overall survival (OS).1-5

    Source: Esmo Open
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ESMO_Open
      ESMO_Open

      Check out the new controversies in #NSCLC article: which second-line strategy after chemo-immunotherapy? https://t.co/up9QrBFSD7 @myESMO @cczielinski

Load More